Kornimate/medical-research-clean huggingface dataset:
prolongation of glp-1 adherence when using continuous glucose monitoring

Conditions: Diabetes Mellitus

Summary: this study is to see if the freestyle libre 3 continuous glucose monitoring system (fsl3) will help prolong the length of time people with diabetes maintain adherence to glucagon-like peptide 1 (glp-1/gip) agonists.

subjects with type 2 diabetes who are newly beginning glp-1 or glp-1/gip drug therapy will be randomized to use either fsl3 or their existing standard of care to manage their diabetes. up to 800 subjects will be enrolled across the united states with 200 evaluable subjects in each group (intervention and control) for a total of 400 evaluable subjects. subjects will be on the study approximately 210 days. subjects will wear one sensor applied to the back of the upper arm and will have a paired smartphone that will be used to start the sensor and collect glucose readings.

Eligibility criteria:
inclusion criteria: 1. subject must be at least 18 years of age. 2. subject must be able to read and understand english. 3. subject must have a type 2 diabetes diagnosis. 4. in the investigator's opinion, subject must meet the criteria for beginning use of glp-1 or gip/glp-1 medications for management of their diabetes. 5. subject is beginning use of glp-1 / gip/glp-1 medication for management of their diabetes. 6. subject must be willing to allow venous samples to be obtained to test hba1c. 7. subject must be willing to either continue using their existing standard of care device or must be willing to use the freestyle libre 3 continuous glucose monitoring system to manage their diabetes throughout the duration of the study. 8. in the investigator's opinion, the subject must be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol. 9. subject must be available to participate in all study visits. 10. subject must be willing and able to provide written signed and dated informed consent. exclusion criteria: 11. subject is a member of the study staff. 12. subject has a diagnosis of type 1 or gestational diabetes. 13. subject is currently using or has previously used glp-1 or gip/glp-1 drugs for any reason. 14. subject is currently using a continuous glucose monitor (cgm) as their standard of care device to manage their diabetes. 15. subject has known allergy to medical grade adhesive, isopropyl alcohol and/or ethyl alcohol used to disinfect skin. 16. subject is taking any type of rapid-acting insulin, including neutral protamine hagedorn (nph) and premix insulin. 17. subject has concomitant medical condition which, in the opinion of the investigator, could interfere with the study or present a risk to the safety or welfare of the subject or study staff. 18. subject currently is participating in another clinical trial. 19. subject is unsuitable for participation due to any other cause as determined by the investigator
two step versus the standard three step approach of the who analgesic ladder for cancer pain relief.

Conditions: Cancer; Pain

Summary: the world health organization analgesic ladder for cancer pain relief is an internationally used approach to managing cancer pain. patients generally start on step 1 of the ladder (paracetamol). as pain increases or is not well controlled on this, they progress to step 2 which involves a stronger pain killer (weak opioid such as codeine). if pain is still not controlled they progress to step 3 of the ladder which is a strong opioid (such as morphine). work to date has suggested that step 2 may be unnecessary and most patients usually require step 3 analgesia. the tvt trial aims to examine the standard approach (step 1-step2-step-3) versus a two step approach (step 1-step 3).


Eligibility criteria:
inclusion criteria: * 18 years of age and over. * patient has a cancer diagnosis (based on radiological, histological, cytological, or operative evidence). those with haematological malignancies are eligible. * cancer related pain - which in the opinion of the clinician is caused by the presence of tumour or metastases. * average pain score \> 4, on a numerical rating scale from 0-10, requiring step 2 analgesia (weak opioid). * patient is able to comply with trial procedures. exclusion criteria: * patients who have received radiotherapy in the previous 6 weeks or are planned to receive radiotherapy during the trial period where in either case, it is expected to affect pain during the trial period. * pain due to surgery in the preceding 4 weeks. * life expectancy less than two months (based on clinical impression). * patients with psychotic disorders or cognitive impairment. * patients who have received regular doses (scheduled doses - not as required dosing) of weak or strong opioids in the preceding two weeks. * patients using immediate release opioids \> 2 doses/24 hours, in the previous 24 hours.
sublingual immunotherapy in alternaria-induced rhinitis

Conditions: Allergic Rhinitis (w/w Asthma) Due to Alternaria Alternata

Summary: respiratory allergy due to alternaria is a relevant clinical problem, and specific immunotherapy may represent a viable treatment option. sublingual immunotherapy (slit) is safe and effective, but data for alternaria are lacking. the study is aimed at assessing the efficacy of a standardized slit in patients sensitised to alternaria, in a randomized, double blind, placebo controlled fashion. patients with rhinitis with/without intermittent asthma, and ascertained allergy to alternaria are enrolled. after a baseline season, slit or matched placebo are given for 10 months. symptoms and rescue medication intake are recorded on diary cards from june to october. skin prick test, specific ige and igg4 and precipitins are measured at baseline and at the end of the study. alternaria spore count is also performed. primary outcome is the change in symptom score in the active vs placebo group. secondary outcomes: changes in rescue medication intake, alternaria specific ige and igg4, skin prick test reactivity.


Eligibility criteria:
inclusion criteria: * allergic rhinitis * symptoms may-october * specific ige to alternaria (skin test/radioallergosorbent \[rast\] test) * age \>14 exclusion criteria: * sensitization to mites, parietaria, mugwort * pregnancy-lactation * malignancies * chronic systemic steroids * previous immunotherapy to alternaria

Keywords: allergic rhinitis alternaria alternata symptom score
the effects of different time reminder on surgical hand scrubing

Conditions: Surgical Site Infection

Summary: when surgical hand scrubing is not done properly, it can negatively affect patient outcomes. in addition to the entire surgical team being able to perform surgical hand scrubing properly, every student studying in the health field who will work in operating rooms should also learn and practice surgical hand washing correctly. in this context, this study aims to evaluate the satisfaction and success of different time reminder systems on students' surgical hand scrubing skills.

this randomized controlled study will carry out sixty-six (music group= 22, alarm group= 22, control group= 22) first year undergraduate operating room services program students. this program places at a vocational school of health services, operating room services programme in ankara turkey.

Eligibility criteria:
inclusion criteria: * to be a first-year students of the operating room services program * to be volunteered exclusion criteria: * previous experience working in the operating room

Keywords: surgical hand scrub skill laboratory satisfaction time reminder
a trial to confirm the efficacy and safety of dasiglucagon in the treatment of hypoglycemia in type 1 diabetes subjects

Conditions: Hypoglycemia; Diabetes Mellitus, Type 1

Summary: the objective of the trial is to demonstrate superiority of dasiglucagon compared to placebo following a single subcutaneous dose administered to subjects with type 1 diabetes mellitus (t1dm) with insulin-induced hypoglycemia. additionally to compare the glycemic response observed after administration dasiglucagon with that of glucagen®.

this was a global, multicenter, randomized, parallel, and double-blind clinical trial confirming the efficacy and safety of dasiglucagon for insulin-induced hypoglycemia in patients with t1dm. the patients were randomized 2:1:1 to receive a single subcutaneous 0.6 mg dose of dasiglucagon, placebo, or a 1 mg dose of glucagen and followed for at least 28 days after receiving treatment.

Eligibility criteria:
inclusion criteria: * female or male subjects with type 1 diabetes mellitus (t1dm) for at least 1 year, diagnostic criteria as defined by the american diabetes association * treated with insulin for t1dm for at least 1 year and with stable insulin treatment (defined as no more than a 10-unit daily variation in total daily insulin dose) 30 days prior to screening * hemoglobin a1c \<10% exclusion criteria: * previously treated with dasiglucagon (previously referred to as zp4207) * known or suspected allergy to trial product(s) or related products * females who are pregnant according to a positive pregnancy test, are actively attempting to get pregnant, or are lactating. * history of hypoglycemic events associated with seizures in the last year prior to screening * history of severe hypoglycemia in the last month prior to screening * active malignancy within the last 5 years * current bleeding disorder, including anti-coagulant treatment * known presence or history of pheochromocytoma (i.e. adrenal gland tumor) or insulinoma (i.e. insulin secreting pancreas tumor) * use of a daily systemic beta-blocker drug, indomethacin, warfarin or anticholinergic drugs in the previous 28 days before day 1 of this trial * clinically significant abnormal ecg at screening as judged by the investigator * donation of blood or plasma in the past month, or in excess of 500 ml within 12 weeks prior to screening * surgery or trauma with significant blood loss within the last 2 months prior to screening * a positive result in the alcohol and/or urine drug screen at the screening visit. significant history of alcoholism or drug abuse as judged by the investigator or consuming more than 24 g alcohol per day for men, or more than 12 g alcohol per day for women

Keywords: dasiglucagon glucagon analog
vpia remifentanil for labour pain to reduce maternal desaturation and improve analgesic titration

Conditions: Labor Pain

Summary: this study is a prospective cohort study aiming to evaluate an improved vpia remifentanil algorithm which would benefit labouring mothers who are unable or unwilling to receive epidural analgesia

this study trials a new vital signs-controlled patient-assisted intravenous analgesia (vpia) regimen using a purpose-built pump that aims to enhance the efficacy, safety and personalization of remifentanil therapy for labouring women. the system studies the parturient's pattern of analgesic use in 15 minute epochs and titrates the demand doses and basal infusion rate to maintain a plasma level of remifentanil that is appropriate for the degree of pain felt. the system incorporates vital signs (pulse oximetry and heart rate values) into the algorithm which would temporarily stop the pump and step down doses accordingly when predefined critical values are reached.

Eligibility criteria:
inclusion criteria: * patients who choose to use parenteral opioid for pain relief with informed consent * patients who refuse labour epidural analgesia or with contraindication to epidural analgesia (eg. thrombocytopaenia, previous thoraco-lumbar spinal instrumentation) * gestational age of \>= 36 weeks exclusion criteria: * patients who are unable to understand instructions given regarding the use of patient controlled analgesia (pca) or unable to self administer pca boluses * patients with difficulty in communication due to language differences * patients with known hypersensitivity to remifentanil or any component of its formulation or to other fentanyl analogue * patients with severe respiratory disease * patients with history of drug dependence of recreational drug abuse * patients with unmanaged foetal bradycardia
quantification of cd163 inflammatory biomarker in chronic periodontitis and diabetic subjects

Conditions: Periodontal Diseases

Summary: the quantification of cd163 will be analysed in the subgingival plaque samples of generalized chronic periodontitis patients with and without diabetes mellitus. the demographic and the periodontal parameters were assessed and the correlated with the quantification of the cd163. the cd163 gene expression was analyzed with rt-pcr and the quantification of cd163 will be done using elisa.

the quantification of cd163 will be analysed in the subgingival plaque samples of generalized chronic periodontitis patients with and without diabetes mellitus. a total of 80 subjects with generalized chronic periodontitis were selected and divided into two groups. group i comprised of 40 subjects who were diagnosed with generalized chronic periodontitis without any systemic conditions. group ii comprised of 40 generalized chronic periodontitis patients with type ii diabetes mellitus. demographic variables such as age, weight, height, bmi and income and the clinical parameters such as plaque index, bleeding on probing, probing pocket depth and clinical attachment level were recorded. subgingival plaque samples were collected from both the groups.the collected samples were subjected to further molecular analysis for the cd163 expression using rt-pcr and for the cd163 quantification using elisa. the elevated levels of cd163 in the subgingival plaque samples of generalized chronic periodontitis subjects with diabetes is expected and the early identification of patients at risk for diabetes mellitus and periodontitis.

Eligibility criteria:
inclusion criteria: 1. patients willing to participate in the study. 2. patients within the age group of 30-65 years (both male and female) 3. patients should have ≥ 10 natural teeth. 4. criteria for selection of generalized chronic periodontitis: * patients having 30% or more sites with clinical attachment loss(cal) ≥ 5mm. 5. criteria for selection of type ii diabetes mellitus: * patients having hba1c \<7 exclusion criteria: 1. patients with systemic conditions such as respiratory diseases, renal disease, liver disease, rheumatoid arthritis, allergy, advanced malignancies and hiv infection will be excluded from the present investigation. 2. patients on drugs such as corticosteroids, antibiotics, aspirin, within 3months of investigation will be excluded. 3. current smokers, individuals who quit smoking less than 6 months. 4. patients who had undergone periodontal therapy within the previous 6 months. 5. pregnant women (which may alter the oral flora).

Keywords: cd163, chronic periodontitis
understanding the genetic basis of familial combined hyperlipidemia in mexican individuals

Conditions: Hyperlipidemia, Familial Combined; Coronary Disease

Summary: familial combined hyperlipidemia (fchl) is an inherited disorder characterized by elevated levels of cholesterol and triglycerides; it often occurs in mexican individuals with coronary heart disease (chd). the purpose of this study is to identify the specific genes that predispose mexican individuals to fchl.

chd is the leading cause of death in mexico. dyslipidemia that is characterized by high total cholesterol, high triglycerides, and low "good" high-density lipoprotein (hdl) cholesterol is a risk factor for developing chd. research has shown that the mexican population has an increased tendency towards dyslipidemia, but it is not known what genetic factors contribute to this predisposition. this study will examine the genetic basis of fchl, which is an inherited form of dyslipidemia characterized by elevated levels of total cholesterol and triglycerides. fchl is a major contributing factor in chd; 20% of individuals with chd under the age of 60 have fchl. the purpose of this study is to identify and characterize the specific dna sequence variations that predispose mexican individuals to fchl. results of this study may aid in the development of appropriate prevention and screening techniques. this study will enroll individuals in mexico who have fchl. participants will attend one study visit for blood collection and dna sampling. family members of participants will be contacted and asked to provide a dna sample also. a select group of participants will return for a second study visit for rna sampling. study researchers will analyze participants' dna and rna samples, as well as two fchl genes identified in previous research studies.

Eligibility criteria:
inclusion criteria: * elevated levels of serum total cholesterol, triglycerides, or both * elevated levels of serum apolipoprotein b (using the mexican population percentiles) exclusion criteria: * tendon xanthomas * kidney disease * thyroid disorder
reliability of myotonometry in the assessment of mechanical properties of thenar muscles

Conditions: Muscular Tone

Summary: this study aimed to (i) assess the reliability of myotonometer measurements in determining the mechanical properties of thenar muscle in healthy individuals and explore gender-based variations in these properties; (ii) examine the relationship between pinch grip strength and these mechanical properties.

investigating the mechanical properties of hand muscles using simple applicable methods such as myotonometer can help to evaluate the effectiveness of programs used in hand rehabilitation, optimize the skills of performance-oriented individuals such as athletes and musicians, and create individualized treatment and training programs. in musculoskeletal-related pathologies such as carpal tunnel syndrome, studying the mechanical properties of the thenar muscles may be important to better understand hand grip strength, hand function and mobility. however, the use of myotonometer in the evaluation of the mechanical properties of the thenar muscles requires a reliability study. accordingly, the aims of our study are: to (i) assess the reliability of myotonometer measurements in determining the mechanical properties of thenar muscle in healthy individuals and explore gender-based variations in these properties; (ii) examine the relationship between pinch grip strength and these mechanical properties.

Eligibility criteria:
inclusion criteria: * being between 18 and 35 years of age * having normal upper extremity function * having a montreal cognitive assessment test (moca) score \> 26 points exclusion criteria: * any neuromuscular or musculoskeletal disease * history of upper limb injury * upper limb surgery within the last 6 months * body mass index (bmi) \> 30 kg/m2.

Keywords: rehabilitation biomechanics assessment skeletal muscle
comparison of the id now and accula point-of-care assays for detection of covid-19

Conditions: Covid-19

Summary: this study is a comparison of the id now covid-19 (abbott) assay to the accula sars-cov-2 (mesa biotech) assay to assist in the identification of infection with covid-19. the tests will be compared for sensitivity, specificity, positive predictive value and negative predictive value.

in response to the pandemic, the food and drug administration (fda) approved several platforms under emergency use authorization (eua). these platforms do not have full fda approval and may be used for covid-19 testing temporarily in a clinical laboratory until the manufacturer receives full fda clearance for use in the u.s. two point of care (poc) platforms with current eua approval are the id now covid-19 (abbott) and the accula sars-cov-2 tests (mesa biotech). both tests are designated as clinical laboratory improvement amendments (clia) waived complexity. pocs play a vital role in the diagnosis of covid-19, especially in laboratories and clinics where testing including molecular assays and serology is not available. the purpose of this study is to compare sars-cov-2 results from clinical specimens on the id now and the accula systems. if the accula system is comparable or demonstrates superior test parameters including sensitivity, then this assay may potentially assist in improving turnaround times for covid-19 results and facilitate reinstating elective procedures. patients with orders for rapid covid-19 testing and who have consented to participate will be included. for these patients one additional clinical specimen, a nasal specimen will be collected from the patient at the same time as the initial specimen for the id now. if there is a discrepancy between the id now and accula test results, an additional specimen (nasal) will be collected from the patient, if possible (i.e. if the patient remains in-house) to confirm the covid-19 results. we will also include patients who did not have an initial swab but tested positive by pcr. they will be swabbed by both systems. this study will evaluate accuracy by comparing accula results to the id now, precision (reproducibility) by repeating select specimens with different users and on different analyzers, limit of detection by diluting commercial sars-cov-2 controls with a known concentration and cross-reactivity by testing known respiratory viruses (including influenza a, b and rsv) on the accula.

Eligibility criteria:
inclusion criteria: * covid-19 testing has been ordered in the emergency dept. or for inpatients in the hospital or patient has already tested positive via pcr. * adult patients * consent obtained exclusion criteria: * testing not ordered or tested negative via pcr. * children * do not consent